<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>About - FDA COVID-19 Vaccine Manufacturing Questions</title>
    <meta name="description" content="About the 248 scientific questions regarding COVID-19 vaccine manufacturing, safety testing, and regulatory oversight">
    <link rel="stylesheet" href="style.css">
</head>
<body>
    <header>
        <h1>Scientific Questions on COVID-19 Vaccine Manufacturing</h1>
        <p class="subtitle">248 Questions for FDA on Manufacturing, Safety Testing, and Regulatory Oversight</p>
        <nav>
            <a href="index.html">Home</a>
            <a href="split-screen.html">Split Screen</a>
            <a href="about.html" class="active">About</a>
            <a href="download.html">Download</a>
        </nav>
    </header>

    <main>
        <section id="executive-summary">
            <h2>Executive Summary</h2>
            <p>This document presents 248 questions to the FDA regarding COVID-19 mRNA vaccine manufacturing processes, safety testing, and regulatory oversight. The questions arise from analysis of regulatory documents, FOIA disclosures, and peer-reviewed research.</p>

            <div class="key-points">
                <h3>Key Areas of Inquiry:</h3>
                <ul>
                    <li>Manufacturing process changes between clinical trials and commercial production</li>
                    <li>Residual DNA contamination and SV40 sequence elements</li>
                    <li>Adequacy of genotoxicity and biodistribution studies</li>
                    <li>Discovery of frameshift proteins</li>
                    <li>Regulatory compliance and disclosure</li>
                </ul>
            </div>
        </section>

        <section id="background">
            <h2>Background</h2>
            <p>These questions have been compiled by David Wiseman, PhD, MRPharmS and Maria Gutschi, BScPhm, PharmD as part of their scientific inquiry into COVID-19 vaccine manufacturing and safety protocols. The questions are based on careful analysis of:</p>
            <ul>
                <li>FDA regulatory documents and guidelines</li>
                <li>Freedom of Information Act (FOIA) disclosures</li>
                <li>Peer-reviewed scientific literature</li>
                <li>Manufacturing process documentation</li>
                <li>Clinical trial data and protocols</li>
            </ul>
        </section>

        <section id="purpose">
            <h2>Purpose</h2>
            <p>The purpose of this compilation is to:</p>
            <ul>
                <li>Promote transparency in vaccine manufacturing and regulation</li>
                <li>Ensure comprehensive safety testing and quality control</li>
                <li>Address scientific concerns raised by researchers and healthcare professionals</li>
                <li>Support informed decision-making by regulatory authorities</li>
                <li>Contribute to the scientific discourse on vaccine safety and efficacy</li>
            </ul>
        </section>

        <section id="categories">
            <h2>Question Categories</h2>
            <div class="category-grid">
                <div class="category-card">
                    <h3>Manufacturing Process</h3>
                    <p>Questions about changes in manufacturing processes between clinical trials and commercial production.</p>
                </div>
                <div class="category-card">
                    <h3>DNA Contamination</h3>
                    <p>Inquiries regarding residual DNA levels and potential contamination in vaccine batches.</p>
                </div>
                <div class="category-card">
                    <h3>Safety Studies</h3>
                    <p>Questions about the comprehensiveness and adequacy of safety testing protocols.</p>
                </div>
                <div class="category-card">
                    <h3>Regulatory Compliance</h3>
                    <p>Examination of regulatory processes and compliance with established guidelines.</p>
                </div>
                <div class="category-card">
                    <h3>Genotoxicity</h3>
                    <p>Questions about potential genetic toxicity and related testing procedures.</p>
                </div>
                <div class="category-card">
                    <h3>Biodistribution</h3>
                    <p>Inquiries about vaccine distribution in the body and related studies.</p>
                </div>
                <div class="category-card">
                    <h3>Frameshift Proteins</h3>
                    <p>Questions regarding the discovery and implications of frameshift proteins.</p>
                </div>
            </div>
        </section>

        <section id="disclaimer">
            <h2>Important Note</h2>
            <p>This website presents scientific questions and analysis for academic and research purposes. It is not intended as medical advice. Healthcare decisions should be made in consultation with qualified medical professionals.</p>
        </section>
    </main>

    <footer>
        <p>&copy; 2025 David Wiseman, PhD, MRPharmS & Maria Gutschi, BScPhm, PharmD</p>
        <p class="disclaimer">This website presents scientific questions and analysis. It is not medical advice.</p>
    </footer>

    <script src="common.js"></script>
</body>
</html>
